Loading...

REVB REVELATION BIOSCIENCES INC US FDA Inspections 8-K Filing

RVLT

RVB

REVELATION BIOSCIENCES INC

(REVB)

2026 8-K

Warrant Approval

Financial Results Update

Warrant Exercise Agreement

FDA Agreement Announcement

Warrants Update

Financial Results Update

Special Meeting Cancelled

Meeting Adjourned

Warrant Exercise Inducement

Positive Clinical Results

Changes to corporate structure

Equity Offerings

Financial Statements

Inflammation Results

Financial Results

Nasdaq Compliance

Corporate Presentation

Stockholder Meeting

Nasdaq Listing Update

Nasdaq Compliance

Warrant Exercise Agreement

Financial Results

Nasdaq Compliance Issues

IL-10 Increase Announcement

Warrant Exercise Agreement

Nasdaq Compliance Issue

Financial Results Announcement

Lawsuit and Judgment

Adjustment of Exercise Pric...

Annual Meeting Results

Financial Results Announcement

Financial Results Announcement

Conference Presentation

Public Offering

Reverse Stock Split

Special Meeting Approval

Financial Results Announcement

Resignation and Appointment...

Financial Results Announcement

Annual Meeting Adjournment

Financial Results and Progr...

Financial Results and Progr...

Compliance with Nasdaq List...

Public Offering

Stock Split and Increase in...

Presentation Update

External Links:

On January 21, 2026, Revelation Biosciences, Inc. announced a successful agreement with the FDA regarding the approval pathway for its study on Acute Kidney Injury (AKI). The company also released an updated corporate presentation available on its website.

AI Assistant

REVELATION BIOSCIENCES INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.